Skip to main content
TipRanks
Go Ultimate75% OFF

eXoZymes (EXOZ) AI Stock Analysis

16 Followers
EXOZ

eXoZymes

(NASDAQ:EXOZ)

Select Model
Rating:38.8Underperform
Price Target:$3.50â–¼(-8.62% Downside)
Action:reiterated
Date:11/14/26

The overall score is severely pressured by the company's pre-revenue status and deep cash burn, which are the most significant risk factors. The persistent technical downtrend across all major moving averages reinforces this weakness. The negative P/E ratio confirms the lack of fundamental earnings support, leaving the stock's value entirely dependent on future pipeline success and continued investor financing.

Positive Factors
Moderate LeverageCurrent leverage is moderate and has improved from the prior year, reducing near-term debt pressure relative to 2025. This provides some financial flexibility, although the benefit is limited because the company remains loss-making and dependent on external funding.
Negative Factors
No Revenue BaseThe absence of revenue means the company has not yet demonstrated commercial traction or operating leverage. It also limits visibility into future cash generation, leaving progress dependent on converting development activity into a viable revenue stream over time.

eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%EXOZ-76.33%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$35.55M
Dividend Yield
―
Average Volume (3M)
9,575
Price to Earnings (P/E)
-3.3
Beta (1Y)
1.20
Revenue Growth
―
EPS Growth
-17.50%
Country
US
Employees
32
Sector
General
Sector Strength
55
Industry
Biotechnology

eXoZymes Business Overview & Revenue Model

Company Description

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc...

How the Company Makes Money

null

eXoZymes Financial Statement Overview

Summary

Pre-revenue biotech with escalating losses and significant cash burn. A recent capital raise improved the balance sheet, but equity is rapidly depleting. Low debt provides some flexibility, but the financial profile remains high-risk and dependent on external funding.

Income Statement

5Very Negative

Balance Sheet

30Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit55.26K0-267.38K0-147.75K-59.41K
EBITDA-11.25M-8.98M-5.59M-1.80M-1.18M-1.15M
Net Income-10.14M-9.16M-5.86M-2.04M-1.40M-1.21M
Balance Sheet
Total Assets5.86M5.97M13.03M3.56M2.69M2.35M
Cash, Cash Equivalents and Short-Term Investments3.26M3.04M9.72M66.53K558.57K547.81K
Total Debt1.00M1.24M1.39M1.61M608.77K720.63K
Total Liabilities3.67M2.57M2.61M3.94M1.31M1.15M
Stockholders Equity2.19M3.40M10.42M-384.32K1.37M1.20M
Cash Flow
Free Cash Flow-7.80M-6.67M-8.90M-1.47M-1.44M-2.01M
Operating Cash Flow-7.36M-6.50M-8.51M-1.18M-1.26M-1.59M
Investing Cash Flow-297.36K-150.22K-359.22K-311.17K-87.21K-312.25K
Financing Cash Flow5.82M-27.71K18.52M1.00M1.36M2.31M

eXoZymes Technical Analysis

Technical Analysis SentimentNegative
Last Price3.83

Price Trends

50DMA5.12Negative
100DMA5.72Negative
200DMA7.42Negative

Market Momentum

MACD-0.28Negative
RSI37.01Neutral
STOCH18.39Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXOZ, the sentiment is Negative. The current price of 3.83 is below the 20-day moving average (MA) of 4.11, below the 50-day MA of 5.12, and below the 200-day MA of 7.42, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 37.01 is Neutral, neither overbought nor oversold. The STOCH value of 18.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EXOZ.

eXoZymes Risk Analysis

eXoZymes disclosed 47 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.Q2, 2026
2.Changes to United States tariff and import/export regulations may have an adverse effect on our business, financial condition and results of operations.Q2, 2026
3.Government Action on tariffs and research grants and other funding may impede our ability to conduct our research and to raise capital by and for our partner companies and other clients.Q2, 2026

eXoZymes Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

EXOZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
NCELNCEL48Neutral$14.05M7.9121.75%―――
BDRXBDRX40Underperform$1.26M-45.43-42.42%――97.97%
EXOZEXOZ39Underperform$35.55M-3.27-376.66%――-17.50%

* General Sector Average

Performance Comparison

-100%-50%0%50%EXOZBDRXADTXNCELVRAXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
EXOZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
EXOZExozymes Inc.3.83-10.69-73.62%
BDRXBiodexa Pharmaceuticals Plc2.40-181.60-98.70%
ADTXAditxt, Inc.0.04-881.24-100.00%
NCELNewcelx Ltd.2.61-0.79-23.24%
VRAXVirax Biolabs Group Ltd. Class A0.61-10.66-94.57%

eXoZymes Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance

eXoZymes Highlights Investor Presentation for Capital Markets Outreach

Positive
Oct 9, 2026

On October 6, 2026, eXoZymes Inc. prepared an investor presentation intended for distribution to investment bankers, offering participants, and existing and prospective investors. The document, filed as an exhibit, is designed to support the company’...

Shareholder Meetings

eXoZymes Sets Date for 2026 Shareholders Meeting

Neutral
Sep 18, 2026

eXoZymes announced that it scheduled its 2026 annual meeting of shareholders for November 13, 2026, setting a formal timeline for its upcoming governance and voting activities. The company established September 15, 2026 as the record date to determin...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026